Charles P. Vega, MD, FAAFP
Clinical Professor, Family Medicine
Director, UC Irvine Program in Medical
Education for the Latino Community
Associate Dean, School of Medicine
University of California, Irvine
Irvine, California
Seema Yasmin, MB, BChir
Director, Stanford Health Communication Initiative
Clinical Assistant Professor, Department of Medicine
Stanford University
Visiting Assistant Professor
Anderson School of Management, UCLA
Palo Alto, California

Target Audience

This course will provide clinicians with strategies to integrate MCED into the primary care setting in an efficient way to improve patient outcomes.

Learning Objectives

Upon completion of this activity, learners should be able to:

  • Review the current epidemiology of cancer incidence and rates of screening in the United States
  • Describe how blood-based cfDNA is used for MCED
  • Discuss current and emerging clinical data on the advantages, disadvantages, accuracy, utility, and cost-effectiveness
  • Integrate MCED and patient counseling into primary care setting

Program Overview

Early detection is an essential step in reducing the burden of cancer. Identifying cancer at its earliest stages improves outcomes by allowing therapy to begin sooner, reducing treatment costs and complexity, minimizing morbidity, and improving mortality and quality of life. Detecting a tumor at a stage when it can be surgically excised or treated with simpler drug regimens can result in 5-year survival rates of more than 90%, while average 5-year survival after detection of a late-stage tumor is only 26%. Limitations of current screening methods include the “one organ at a time” approach, which requires use of different (and often expensive) modalities for each type of cancer. Multi-Cancer Early Detection (MCED) tests can analyze blood samples to detect genetic signals from tumors at the earliest stages of their development. These tests, also known as liquid biopsies, have been shown to efficiently identify more than 50 types of cancer at earlier stages, with a high degree of sensitivity and specificity, and can even identify the specific organ in which the tumor is located.

This webcast was recorded at the Emerging Challenges and Clinical Updates Live Virtual Broadcast and is being used with the permission of the presenters.

Physician Accreditation Statement

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP Provider Statement

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 1.0 contact hour (which includes 0 hours of pharmacology).

NACE Contact Information

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 60% or higher on the posttest and complete the program evaluation.

Fee Information

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Accredited education provided by the National Association for Continuing Education (NACE) must demonstrate balance, independence, objectivity, and scientific rigor. All individuals in a position to influence content of NACE accredited education, are required to disclose all financial relationships with ineligible companies within the previous 24-month period, regardless of relevance to the education. All relevant financial relationships and potential conflicts of interest have been mitigated.

NACE defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Charles P. Vega has disclosed the following financial relationships:

Consultant: GlaxoSmithKline, Johnson & Johnson

Faculty, planners, and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure of Unlabeled/Investigational Uses of Products

The content of the presentations may include discussion of unapproved or investigational uses of product or devices.

Begin Activity
available resources
meeting slides
linked resources
Suggested Reading

Multi-Cancer Early Detection in Primary Care

What You Need to Know About New Blood-Based Screening Tools